Inherent weaknesses of the current ICD coding system regarding idiopathic pulmonary fibrosis

European Respiratory Journal

Volumn 45, Issue 4, 2015, Pages 1194-1196

  Tzilas, Vasilios ^a   Bouros, Demosthenes ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHIOLITIS; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; DISEASE CLASSIFICATION; FIBROSING ALVEOLITIS; HUMAN; ICD-10-CM; INCIDENCE; INTERSTITIAL PNEUMONIA; LETTER; LUNG EMPHYSEMA; LUNG FIBROSIS; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; CLASSIFICATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FEMALE; IMMUNOHISTOCHEMISTRY; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; NEEDLE BIOPSY; NEEDS ASSESSMENT; PATHOLOGY; PROCEDURES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STANDARDS; SURVIVAL; TRENDS;

BIOPSY, NEEDLE; DISEASE PROGRESSION; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOHISTOCHEMISTRY; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; NEEDS ASSESSMENT; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84926459215     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00205914     Document Type: Letter

References (13)

1. Ley B, Collard HR. Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol 2013; 5: 483-492.
2. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
3. Travis WD, Costabel U, Hansell DM, et al. An Official American Thoracic Society/European Respiratory Society statement: update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2013; 188: 733-748.
4. th Revision. Geneva, WHO, 2010.
5. Bouros D, Nicholson AC, Polychronopoulos V, et al. Acute interstitial pneumonia. Eur Respir J 2000; 15: 412-418.
6. Flaherty KR, Andrei A, King TE Jr, et al. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med 2007; 175: 1054-1060.
7. Ryerson CJ, Hartman T, Elicker BM, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest 2013; 144: 234-240.
8. Mejia M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009; 136: 10-15.
9. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. Lancet 2011; 377: 1760-1769.
10. Bouros D. Pirfenidone for idiopathic pulmonary fibrosis. Lancet 2011; 377: 1727-1729.
11. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092.
12. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082.
13. Tzouvelekis A, Paspaliaris V, Koliakos G, et al. A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. J Transl Med 2013; 11: 171.